核心蛋白聚糖生物学的研究进展  

Research Progress in the Biology of Decorin

作　　者：袁媛[1] 周静[1] 姜政[1] 

机构地区：[1]重庆医科大学附属第一医院消化内科,重庆400016

出　　处：《医学综述》2011年第9期1303-1306,共4页Medical Recapitulate

摘　　要：核心蛋白聚糖(DCN)属富含亮氨酸小分子蛋白多糖家族成员之一。转化生长因子β(TGF-β)与其受体结合后导致细胞外基质过度沉积,DCN通过与TGF-β结合并将其中和以产生抗纤维化和抑制瘢痕形成的作用。同时DCN亦通过激活表皮生长因子受体(EGFR)/促分裂原活化蛋白激酶/p21信号通路和抑制EGF-EGFR介导的促细胞增殖信号通路等机制来抑制肿瘤细胞增殖与转移。基于DCN以上两方面的生物活性,加之源于人体自身产生,所以重组产品免疫原性较低,提示DCN对于慢性纤维化和肿瘤等疾病的防治具有潜在的药用开发价值。Decorin（DCN） is one of the leucine-rich proteoglycan familly of small molecules.Substantial evidence shows that DCN can interrupt transforming growth factor-β（TGF-β） binding to its receptor and reduce the excessive deposition of extracellular matrix.DCN plays an anti-fibrotic role and inhibits the formation of scar by binding or neutralizating TGF-β.DCN can also inhibit tumor cell proliferation and metastasis by activating epidermal growth factor receptor（EGFR）/MAPK/p21 signaling pathway and inhibiting the signaling pathway that promotes cell proliferation by EGF-EGFR.Due to the above two biological activities and its human origin,recombinant DCN has a low immunogenicity,suggesting that DCN has a pharmacological potential in the treatment of chronic fibrosis and cancers.

关 键 词：核心蛋白聚糖 表皮生长因子受体 抗纤维化 抗肿瘤 

分 类 号：R575.2[医药卫生—消化系统]